Pulmonary delivery of antitubercular drugs using spray-dried lipid–polymer hybrid nanoparticles

References

• Ahmad Z, Pandey R, Sharma S, Khuller GK. 2006. Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential. Indian J Chest Dis Allied Sci. 48:171–176.
   PubMedGoogle Scholar
• Arifin DY, Lee LY, Wang CH. 2006. Mathematical modeling and simulation of drug release from microspheres: implications to drug delivery systems. Adv Drug Deliv Rev. 58:1274–1325.
   PubMed Web of Science ®Google Scholar
• Bhardwaj A, Kumar L, Narang R, Murthy R. 2013. Development and characterization of ligand-appended liposomes for multiple drug therapy for pulmonary tuberculosis. Artif Cell Nanomed Biotechnol. 41:52–59.
   PubMed Web of Science ®Google Scholar
• Chan JM, Zhang L, Yuet KP, Liao GV, Rhee JW, Langer R, Farokhzad OC. 2009. PLGA–lecithin–PEG core–shell nanoparticles for controlled drug delivery. Biomaterials. 30:1627–1634.
   PubMed Web of Science ®Google Scholar
• Cheow WS, Hadinoto K. 2011. Factors affecting drug encapsulation and stability of lipid–polymer hybrid nanoparticles. Colloids Surf B: Biointerfaces. 85:214–220.
   PubMed Web of Science ®Google Scholar
• Chono S, Tanino T, Seki T, Morimoto K. 2008. Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections. J Control Release. 127:50–58.
   PubMed Web of Science ®Google Scholar
• Corrigan CO, Corrigan OI, Healy AM. 2006. Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers. Int J Pharm. 322:22–30.
   PubMed Web of Science ®Google Scholar
• Florence AT, Law TK, Whateley TL. 1985. Nonaqueous foam structures from osmotically swollen W/O/W emulsion droplets. J Colloid Interface Sci. 107:584–588.
   Web of Science ®Google Scholar
• Gao Y, Zuo J, Bou-Chacra N, de Jesus Andreoli Pinto T, Clas SD, Walker RB, Lobenberg R. 2013. In Vitro Release Kinetics of Antituberculosis Drugs from Nanoparticles Assessed Using a Modified Dissolution Apparatus. BioMed Res Int. 1–9.
   PubMed Web of Science ®Google Scholar
• Geller DE. 2009. Aerosol antibiotics in cystic fibrosis. Respir Care. 54:658–670.
   PubMed Web of Science ®Google Scholar
• Kahana LM, Spino M. 1991. Ciprofloxacin in patients with mycobacterial infections: experience in 15 patients. DICP. 25:919–924.
   PubMedGoogle Scholar
• Kaur R, Garg T, Gupta UD, Gupta P, Rath G, Goyal AK. 2014. Preparation and characterization of spray-dried inhalable powders containing nanoaggregates for pulmonary delivery of anti-tubercular drugs. Artif Cells Nanomed Biotechnol. 1–6.
   PubMed Web of Science ®Google Scholar
• Kho K, Hadinoto K. 2011. Optimizing aerosolization efficiency of dry-powder aggregates of thermally-sensitive polymeric nanoparticles produced by spray freeze- drying. Powder Technol. 214:169–176.
   Web of Science ®Google Scholar
• Kingsley J, Dou H, Morehead J, Rabinow B, Gendelman H, Destache C. 2006. Nanotechnology: A Focus on Nanoparticles as a Drug Delivery System. J Neuroimmune Pharmacol. 1:340–350.
   PubMed Web of Science ®Google Scholar
• Kumbhar DD, Pokharkar VB. 2013a. Engineering of nanostructured lipid carrier for the poorly water-soluble drug, bicalutamide: physicochemical investigations. Colloid Surface A. 416:32–42.
   Web of Science ®Google Scholar
• Kumbhar DD, Pokharkar VB. 2013b. Physicochemical investigations on an engineered lipid–polymer hybrid nanoparticle containing a model hydrophilic active, zidovudine. Colloid Surface A. 436: 714–725.
   Web of Science ®Google Scholar
• Labiris NR, Dolovich MB. 2003. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Brit J Clin Pharmacol. 56:588–599.
   PubMed Web of Science ®Google Scholar
• Li SD, Huang L. 2008. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm. 5:496–504.
   PubMed Web of Science ®Google Scholar
• Masood S, Farah F, Abdul S, Shahid A, Tariq B, Karamat K, Mubashir A. 2010. Efficacy of amikacin and ciprofloxacin against clinical isolates of Mycobacterium tuberculosis. J Ayub Med Coll Abbottabad. 22:101–103.
   Google Scholar
• Muttil P, Kaur J, Kumar K, Yadav AB, Sharma R, Mishra A. 2007. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur J Pharm Sci. 32:140–150.
   PubMed Web of Science ®Google Scholar
• Oliveira BF, Santana MHA, Re MI. 2005. Spray-dried chitosan microspheres cross-linked with d,l-glyceraldehyde as a potential drug delivery systemml: preparation and characterization. Brazil J Chem Eng. 22:353–360.
   Web of Science ®Google Scholar
• Pandey R, Ahmad Z. 2011. Nanomedicine and experimental tuberculosis: facts, flaws, and future. Nanomedicine. 7:259–272.
   PubMed Web of Science ®Google Scholar
• Pardeshi CV, Belgamwar VS, Tekade AR, Surana SJ. 2013. Novel surface modified polymer–lipid hybrid nanoparticles as intranasal carriers for ropinirole hydrochloride: in vitro, ex vivo and in vivo pharmacodynamic evaluation. J Mater Sci Mater Med. 24:2101–2115.
   PubMed Web of Science ®Google Scholar
• Patil J, Sarasija S. 2012. Pulmonary drug delivery strategies: A concise, systematic review. Lung India. 29:44.
   PubMedGoogle Scholar
• Pourshahab PS, Gilani K, Moazeni E, Eslahi H, Fazeli MR, Jamalifar H. 2011. Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid. J Microencapsulation. 28:605–613.
   PubMed Web of Science ®Google Scholar
• Rabbani NR, Seville PC. 2005. The influence of formulation components on the aerosolization properties of spray-dried powders. J Control Release. 110:130–140.
   PubMed Web of Science ®Google Scholar
• Rambali B, Baert L, Massart DL. 2001. Using experimental design to optimize the process parameters in fl uidized bed granulation on a semi-full scale. Int J Pharm. 220:149–160.
   PubMed Web of Science ®Google Scholar
• Rane S, Prabhakar B. 2013. Optimization of paclitaxel containing pH-sensitive liposomes by 3 factor, 3 level box-behnken design. Indian J Pharm Sci. 75:420–426.
   PubMed Web of Science ®Google Scholar
• Rao BS, Murthy KVR. 2000. Preparation and in vitro evaluation of chitosan matrices cross-linked by formaldehyde vapours. Drug Dev Ind Pharm. 26:1085–1090.
   PubMed Web of Science ®Google Scholar
• Rogueda PGA, Traini D. 2007. The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects. Expert Opin Drug Deliv. 4:595–606.
   PubMed Web of Science ®Google Scholar
• Salvador-Morales C, Zhang L, Langer R, Farokhzad OC. 2009. Immunocompatibility properties of lipid–polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials. 30:2231–2240.
   PubMed Web of Science ®Google Scholar
• Sanchez LC, Furlanetto S, Fernandez Arevalo M, Alvarez Fuentes J, Rabasco AM, Faucci MT, et al. 2002. Didanosine Extended release matrix tablets: Optimization of formulation variables using statistical experimental design. Int J Pharm. 237:107–118.
   PubMed Web of Science ®Google Scholar
• Sinsuebpol C, Chatchawalsaisin J, Kulvanich P. 2013. Preparation and in vivo absorption evaluation of spray dried powders containing salmon calcitonin loaded chitosan nanoparticles for pulmonary delivery. Drug Dev Dev Ther. 7:861–873.
   PubMed Web of Science ®Google Scholar
• Singh B, Dahiya M, Saharan V, Ahuja V. 2005. Optimizing Drug Delivery Systems Using Systematic “Design of Experiments.” Part II: Retrospect and Prospects. Crit Rev Ther Drug. 22:215–293.
   PubMed Web of Science ®Google Scholar
• Solanki AB, Parikh JR, Parikh RH. 2007. Formulation and optimization of piroxicam proniosomes by 3-factor, 3 level Box-Behnken Design. AAPS Pharm Sci Tech. 8:43–49.
   Web of Science ®Google Scholar
• Thevenot J, Troutier AL, David L, Delair T, Ladaviere C. 2007. Steric stabilization of lipid/polymer particle assemblies by poly (ethylene glycol)-lipids. Biomacromolecules. 8:3651–3660.
   PubMed Web of Science ®Google Scholar
• Wang Y, Kho K, Cheow WS, Hadinoto K. 2012. A comparison between spray drying and spray freeze drying for dry powder inhaler formulation of drug-loaded lipid–polymer hybrid nanoparticles. Int J Pharm. 424:98–106.
   PubMed Web of Science ®Google Scholar
• Xie S, Wang S, Zhao B, Han C, Wang M, Zhou W. 2008. Effect of PLGA as a polymericemulsifier on preparation of hydrophilic protein-loaded solid lipid nanoparticles. Colloids Surf B Biointerfaces. 67:199–204.
   PubMed Web of Science ®Google Scholar
• Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. 2003. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 167:1472–1147.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C, Xie C. 2010. DDSolver: an add-in program for modeling and comparison of drug d issolution profiles. AAPS J. 12:263–271.
   PubMed Web of Science ®Google Scholar